V. Vignard

发表

An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context

B. Dréno, Y. Godet, A. Moreau-Aubry, 2010, Cancer Immunology, Immunotherapy.

Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients

B. Dréno, Y. Godet, V. Vignard, 2007, Cancer Immunology, Immunotherapy.

Double Positive CD4CD8 αβ T Cells: A New Tumor-Reactive Population in Human Melanomas

B. Dréno, Y. Godet, A. Moreau-Aubry, 2010, PloS one.

Non-Coding RNAs in Cutaneous Melanoma Development, Progression and Dissemination

V. Vignard, D. Fradin, 2018 .

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.

J. Mosnier, D. Laplaud, S. Conchon, 2020, The Journal of clinical investigation.

Frequent occurrence of high affinity T cells against MELOE‐1 makes this antigen an attractive target for melanoma immunotherapy

D. Schadendorf, B. Dréno, Y. Godet, 2010, European journal of immunology.

TFrequencies of Additional MelanA-Specific Patients Is Followed by Increased MelanA-Specific CTL Clones in Melanoma Adoptive Transfer of Tumor-Reactive Jotereau and

K. Echasserieau, B. Dréno, A. Lim, 2005 .

Recognition of pleural mesothelioma by mucin-1(950–958)/human leukocyte antigen A*0201-specific CD8+ T-cells

V. Vignard, N. Labarrière, M. Grégoire, 2011, European Respiratory Journal.

Rare pathogenic variants in WNK3 cause X-linked intellectual disability.

R. Redon, J. Rosenfeld, D. Grozeva, 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients

B. Dréno, V. Vignard, A. Khammari, 2021, Cancer Immunology, Immunotherapy.

Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients

V. Quillien, V. Vignard, N. Labarrière, 2006, Clinical Cancer Research.

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

E. Chiocca, B. Dréno, F. Tangy, 2018, Oncoimmunology.

Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma.

V. Vignard, N. Labarrière, D. Fradin, 2019, Cellular immunology.

Bi-allelic loss-of-function variants in TMEM147 cause moderate to profound intellectual disability with facial dysmorphism and pseudo-Pelger-Huët anomaly

M. Tartaglia, R. Maroofian, H. Houlden, 2022, American journal of human genetics.

Overexpression of Meloe Gene in Melanomas Is Controlled Both by Specific Transcription Factors and Hypomethylation

A. Moreau-Aubry, V. Vignard, F. Lang, 2013, PloS one.

ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring—even in hands of ELISPOT-inexperienced investigators

K. Silina, P. Lehmann, V. Vignard, 2009, Journal of immunotoxicology.

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy

R. Gottardo, S. Riddell, B. Dréno, 2020, Journal for ImmunoTherapy of Cancer.

Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy.

B. Dréno, V. Vignard, A. Khammari, 2017, Cancer research.

PD-1 expression conditions T cell avidity within an antigen-specific repertoire

B. Dréno, V. Vignard, A. Khammari, 2015, Oncoimmunology.

MicroRNAs in Tumor Exosomes Drive Immune Escape in Melanoma

V. Vignard, N. Labarrière, D. Fradin, 2019, Cancer Immunology Research.

The Melanoma Antigens MELOE-1 and MELOE-2 Are Translated from a Bona Fide Polycistronic mRNA Containing Functional IRES Sequences

W. Mikulits, A. Moreau-Aubry, V. Vignard, 2013, PloS one.

Immunoregulatory Function of IL-27 and TGF-&bgr;1 in Cardiac Allograft Transplantation

K. Wood, C. Usal, E. Chiffoleau, 2012, Transplantation.

Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer

B. Dréno, V. Vignard, A. Khammari, 2011, PloS one.

Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes

A. Jarry, V. Vignard, N. Labarrière, 2020, Journal for ImmunoTherapy of Cancer.

Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells1

K. Echasserieau, B. Dréno, A. Lim, 2005, The Journal of Immunology.

MELOE-1 Antigen Contains Multiple HLA Class II T Cell Epitopes Recognized by Th1 CD4+ T Cells from Melanoma Patients

B. Dréno, A. Rogel, V. Vignard, 2012, PloS one.

Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.

B. Dréno, V. Vignard, A. Khammari, 2009, The Journal of investigative dermatology.

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency

B. Dréno, Y. Godet, A. Moreau-Aubry, 2008, The Journal of experimental medicine.

A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination

A. Rogel, V. Vignard, F. Lang, 2011, Cancer Immunology, Immunotherapy.

A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients

D. Schadendorf, B. Dréno, Y. Godet, 2009, Cancer Immunology, Immunotherapy.

TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features

B. Dréno, Zhongen Wu, V. Vignard, 2018, Front. Immunol..

Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder.

Whitney J. Smith, R. Redon, J. Rosenfeld, 2022, American journal of human genetics.

PSMC3 proteasome subunit variants are associated with neurodevelopmental delay and type I interferon production

Meghan C Towne, E. Eichler, H. Hakonarson, 2023, Science Translational Medicine.

Loss-of-function variants in CUL3 cause a syndromic neurodevelopmental disorder

Jill A. Madden, J. Rosenfeld, J. R. Younce, 2023, medRxiv.

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency

B. Dréno, Y. Godet, A. Moreau-Aubry, 2008, The Journal of experimental medicine.